OBJECTIVES: To perform an up-to-date meta-analysis of trials to evaluate the risk of pazopanib-related hematologic toxicities. METHODS: Several databases were searched including PubMed, Scopus, Web of Science, trial registries and Cochrane databases. Eligible studies were phase II and III prospective clinical trials of patients with cancer assigned drug pazopanib 800 mg/day with data on hematologic toxicities. Overall incidence rates, relative risk (RR), and 95 % confidence intervals (CI) were calculated employing fixed or random effects models depending on the heterogeneity of the included trials. RESULTS: A total of 3972 patients were included from 17 clinical trials. The incidences of pazopanib-associated all-grade anemia, neutropenia, thrombocytopenia and lymphopenia were 30.5%, 26.9%, 20.6% and 32.8%, respectively. The incidences of high-grade events were 3.9%, 4.0%, 2.8% and 5.8%, respectively. Pazopanib is associated with significant risk of all-grade (RR = 4.20, 95% CI, 3.16 – 5.56) and high-grade (RR = 6.12, 95% CI, 3.07 – 12.23) neutropenia, all-grade (RR = 6.27, 95%, CI, 4.10 – 9.57) and high-grade (RR = 3.59, 95% CI, 1.30 -9.91) thrombocytopenia. CONCLUSIONS: This is the first meta-analysis to demonstrate a significantly increased risk of all-grade and high-grade neutropenia and thrombocytopenia with pazopanib compared with control. Clinicians should be aware of this risk and provide close monitoring in patients receiving these therapies.